Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS Education Paradox: How Can Sponsors Create Independent CME?

Executive Summary

CME content must be developed without influence from drug companies, but FDA says it does not have the resources to write a blueprint for every risk management education program as it did for the opioid REMS.


Related Content

REMS Enhancements Could Include Provider Education Credits
Risk Management Professional Society Would Aim To Improve REMS Performance
Opioid Physician Training Options Remain Limited After Initial Launch
REMS For Qsymia Limits Distribution, But Vivus To Explore Expanding Access
Opioid Training Syllabus Increases Emphasis On Patient Monitoring In Final REMS Blueprint
Opioid Prescriber Knowledge Assessment Due Year After Patient Assessment
Opioid REMS Requires Sponsors To Launch Prescriber Training CME Within 9 Months
ACCME Poses Four Conditions For Acceptable Industry-Supported CME


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts